Carl Zeiss Meditec Logo
DE0005313704
531370
AFX.DE

Carl Zeiss Meditec

Caricamento quotazioni...

Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Carl Zeiss expands presence in South Korea and sees Asia as core market

    At the Asia-Pacific summit in Seoul, Carl Zeiss CEO Andreas Pecher emphasized that Zeiss is expanding its innovation and market proximity in South Korea and recently opened a new research center to better serve customers like Samsung and SK Hynix. Corporate leaders are calling for a more pragmatic German industrial policy as value chains diversify amid the AI boom and geopolitical tensions. Many companies still view China as an important market but also see opportunities in South Korea, ASEAN countries and India; at the same time managers warn that Germany’s relative cost and growth disadvantages make investment more difficult. » Altro su faz.net


  • Carl Zeiss launches cost-cutting program and steps up innovation drive

    Under CEO Andreas Pecher, Carl Zeiss is consolidating an ambitious cost-cutting program with annual savings of “several hundred million” over three years to free up funds for the innovation program “Beyond.” The focus remains the semiconductor division, supplying high-end projection optics for ASML, while the group is also seeking new future fields such as spatial biology, photonics and precision farming. Restructuring measures include divestments (e.g., sports optics) and staffing adjustments; up to 700 jobs worldwide in the medical technology unit could be affected. The goal is to make Zeiss grow profitably in the long term and to provide resources for scalable, market-ready innovations. » Altro su faz.net


  • Carl Zeiss Meditec: Bronwyn Brophy O'Connor to become CEO on December 1

    Bronwyn Brophy O'Connor will succeed Andreas Pecher as CEO of Carl Zeiss Meditec on December 1. At the same time she will join the management board of the parent company and take responsibility for its medical technology division. The executive previously worked at Vitrolife, brings more than 25 years of industry experience and has worked for Thermo Fisher and Medtronic, among others; Pecher had recently launched a cost‑saving program that could cut up to 1,000 jobs. » Altro su wiwo.de


  • Carl Zeiss Meditec defends 200-day line after downgrade by Goldman Sachs

    After a sell recommendation from Goldman Sachs, Carl Zeiss Meditec’s stock came under pressure and fell intraday by as much as around 7 percent, but remained just above the 200-day line at €28.98 and later reduced the loss to about 2 percent. Goldman Sachs justified the downgrade with further deteriorated sales prospects and the assessment that these risks were not yet sufficiently reflected in the valuation. The stock is down more than 20 percent year-to-date. » Altro su finanzen.net


  • Carl Zeiss Meditec receives FDA 510(k) clearance for cloud-based ophthalmology software

    Carl Zeiss Meditec has received 510(k) clearance from the US FDA for ZEISS CLINIC 360, a cloud- and browser-based software that consolidates diagnostic imaging data, EMR, and practice management systems into a unified patient view. The solution integrates data from ZEISS devices and DICOM-capable third-party devices and offers tools for monitoring glaucoma progression, trend analysis, and case/report exchange via “ZEISS Collaborative Care.” ZEISS CLINIC 360 will be available by subscription in the US from early fall 2026; ZEISS FORUM will remain available for users who prefer on-premise solutions. The product is not approved for use in humans in the EU. » Altro su de.investing.com

Nel 2026, Carl Zeiss Meditec ha già distribuito 0,55 € di dividendi. L'ultimo pagamento è avvenuto a marzo.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Carl Zeiss Meditec ha registrato ricavi pari a 562,72 Mln € e un utile netto di 55,03 Mln €
(EUR) giugno 2026
YoY
Ricavi 562,72 Mln 2,38%
Utile lordo 302,28 Mln 4,34%
Utile netto 55,03 Mln 93,94%
EBITDA 74,87 Mln 57,11%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
3,06 Mld €
Numero di azioni
87,54 Mln
Massimo/minimo a 52 settimane
46,54 € - 22,62 €
Rendimento da dividendo
1,57%
Dividendi TTM
0,55 €
Beta
1,35
Rapporto P/E
20,96
Rapporto PEG
-6,04
Rapporto P/B
1,43
Rapporto P/S
1,16

Profilo aziendale

Carl Zeiss Meditec AG opera come azienda di tecnologia medica in Germania, nel resto d'Europa, negli Stati Uniti, in Asia e a livello internazionale. Opera in due segmenti, Dispositivi Oftalmici e Microchirurgia. Il segmento Dispositivi Oftalmici offre prodotti e soluzioni per la diagnosi e il trattamento delle malattie oculari; e sistemi e materiali di consumo per interventi di cataratta, retina e chirurgia refrattiva. Si rivolge a oftalmologi e optometristi che esercitano la professione, nonché a medici e chirurghi in ospedali e centri di chirurgia ambulatoriale. Il segmento Microchirurgia offre soluzioni di visualizzazione per trattamenti chirurgici invasivi; e soluzioni nei settori dell'otorinolaringoiatria, della chirurgia plastica e ricostruttiva, odontoiatrica e spinale. Si rivolge a medici di diverse discipline e ad ospedali. La società è stata fondata nel 1846 ed ha sede a Jena, in Germania. Carl Zeiss Meditec AG è una controllata di Carl Zeiss AG.

Nome
Carl Zeiss Meditec
CEO
Andreas Pecher
Sede centrale Jena, th
Germania
Sito web
Settore
Sanità
Industria
Fornitori e servizi sanitari
Quotazione in borsa
22/03/2000
Dipendenti 5784

Simboli di borsa

Borsa Simbolo
XETRA
AFX.DE
Pnk
CZMWF
Frankfurt
AFX.F
Düsseldorf
AFX.DU
Hamburg
AFX.HM
Milan
1AFX.MI
London
0DHC.L
SIX
AFX.SW
München
AFX.MU
Wien
AFX.VI
🍪

Parqet  usa i cookie. Scopri di più